胰岛素甘精类似物进入市场相关的变化。
Changes Associated With the Entry of a Biosimilar in the Insulin Glargine Market.
机构信息
Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
出版信息
JAMA Intern Med. 2021 Oct 1;181(10):1405-1407. doi: 10.1001/jamainternmed.2021.2769.
Abstract
This study explores the shifts in total US sales and net prices for all 3 insulin glargine products from quarter 1 of 2010 through quarter 2 of 2020.
摘要
本研究探讨了 2010 年第 1 季度至 2020 年第 2 季度所有 3 种甘精胰岛素产品的总销售额和净价格在美国的变化情况。
相似文献
1
Changes Associated With the Entry of a Biosimilar in the Insulin Glargine Market.胰岛素甘精类似物进入市场相关的变化。
JAMA Intern Med. 2021 Oct 1;181(10):1405-1407. doi: 10.1001/jamainternmed.2021.2769.
2
Real-World Budget Impact of the Adoption of Insulin Glargine Biosimilars in Primary Care in England (2015-2018).英格兰初级医疗中采用甘精胰岛素生物类似药的真实世界预算影响（2015 - 2018年）
Diabetes Care. 2020 Aug;43(8):1767-1773. doi: 10.2337/dc19-2395. Epub 2020 Jun 11.
3
Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications.在欧洲，包括生物类似药在内的长效胰岛素类似物的使用趋势：发现与启示。
Biomed Res Int. 2021 Oct 11;2021:9996193. doi: 10.1155/2021/9996193. eCollection 2021.
4
Differences Between Managed Care and Fee-for-Service Medicaid in the Use of Generics for High-Rebate Drugs: The Cases of Insulin Glargine and Glatiramer.管理式医疗与按服务收费的医疗补助制度在高回扣药物使用仿制药方面的差异：以甘精胰岛素和格拉替雷为例。
J Manag Care Spec Pharm. 2020 Feb;26(2):154-159. doi: 10.18553/jmcp.2020.26.2.154.
5
In brief: Semglee - insulin glargine interchangeable with Lantus.简而言之：赛姆利（Semglee）——甘精胰岛素可与来得时（Lantus）互换。
Med Lett Drugs Ther. 2021 Oct 4;63(1634):159-160.
6
Long-term safety and effectiveness of biosimilar insulin glargine in Japanese patients with diabetes mellitus in routine clinical practice: results of a post-marketing safety study.在常规临床实践中，生物类似胰岛素 glargine 在日本糖尿病患者中的长期安全性和有效性：一项上市后安全性研究结果。
Curr Med Res Opin. 2020 Jun;36(6):947-958. doi: 10.1080/03007995.2020.1754182. Epub 2020 Apr 23.
7
The impact of biosimilar insulins on the diabetes landscape.生物类似胰岛素对糖尿病领域的影响。
J Manag Care Spec Pharm. 2022 Jan;28(1):91-98. doi: 10.18553/jmcp.2021.21253. Epub 2021 Nov 2.
8
[Effectiveness of an intervention strategy in the biosimilar glargine prescription pattern in primary care].[一项干预策略对基层医疗中生物类似物甘精胰岛素处方模式的有效性]
Aten Primaria. 2019 Jun-Jul;51(6):350-358. doi: 10.1016/j.aprim.2018.02.012. Epub 2018 May 31.
9
Biosimilar Insulin and Costs: What Can We Expect?生物类似物胰岛素与成本：我们能期待什么？
J Diabetes Sci Technol. 2015 Sep 8;10(2):457-62. doi: 10.1177/1932296815605337.
10
Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria.在保加利亚，1 型和 2 型糖尿病成人患者中，德谷胰岛素相对于甘精胰岛素 U100 的成本效益分析。
BMC Endocr Disord. 2019 Dec 3;19(1):132. doi: 10.1186/s12902-019-0460-6.
引用本文的文献
1
State Substitution Laws and Uptake of an Interchangeable Insulin Biosimilar.州替代法与可互换胰岛素生物类似药的使用情况
JAMA Health Forum. 2025 Apr 4;6(4):e250406. doi: 10.1001/jamahealthforum.2025.0406.
2
Role of biosimilar introduction on insulin glargine prices: a retrospective analysis in 28 European countries.生物类似药引入对甘精胰岛素价格的影响：28个欧洲国家的回顾性分析
BMJ Open. 2025 Jan 30;15(1):e090484. doi: 10.1136/bmjopen-2024-090484.
3
Lessons From Insulin: Policy Prescriptions for Affordable Diabetes and Obesity Medications.从胰岛素中吸取的教训：制定负担得起的糖尿病和肥胖症药物的政策处方。
Diabetes Care. 2024 Aug 1;47(8):1246-1256. doi: 10.2337/dci23-0042.
4
Filgrastim and infliximab biosimilar uptake in Medicare Advantage compared with Traditional Medicare, 2016-2019.2016-2019 年医疗保险优势计划与传统医疗保险相比，采用非格司亭和英夫利昔单抗生物类似药的情况。
J Manag Care Spec Pharm. 2024 Jan;30(1):15-21. doi: 10.18553/jmcp.2024.30.1.15.
5
Utilization, user characteristics, and adverse outcomes of insulin glargine originators and follow-on drug in patients with diabetes in the United States.美国糖尿病患者中甘精胰岛素原研药和生物类似药的使用情况、用户特征和不良结局。
J Manag Care Spec Pharm. 2023 Jul;29(7):842-847. doi: 10.18553/jmcp.2023.29.7.842.
6
Comparison of Price Index Methods and Drug Price Inflation Estimates for Hepatitis C Virus Medications.比较丙型肝炎病毒药物的价格指数方法和药品价格通胀估计。
JAMA Health Forum. 2023 Jun 2;4(6):e231317. doi: 10.1001/jamahealthforum.2023.1317.
7
Prescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary.《关于生物类似药采用的处方医生观点和临床药理学的潜在作用：研讨会总结》。
Clin Pharmacol Ther. 2023 Jan;113(1):37-49. doi: 10.1002/cpt.2765. Epub 2022 Nov 4.
8
The impact of biosimilar insulins on the diabetes landscape.生物类似胰岛素对糖尿病领域的影响。
J Manag Care Spec Pharm. 2022 Jan;28(1):91-98. doi: 10.18553/jmcp.2021.21253. Epub 2021 Nov 2.
Zotero 插件